Literature DB >> 24750552

VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis.

Elisabet Sánchez1, Juan C Nieto, Ana Boullosa, Silvia Vidal, Francesc J Sancho, Giacomo Rossi, Pau Sancho-Bru, Rosa Oms, Beatriz Mirelis, Cándido Juárez, Carlos Guarner, Germán Soriano.   

Abstract

BACKGROUND & AIMS: Probiotics can prevent pathological bacterial translocation in cirrhosis by modulating intestinal microbiota and improving gut barrier and immune disturbances. To evaluate the effect of probiotic VSL#3 on bacterial translocation, intestinal microbiota, gut barrier and inflammatory response in rats with experimental cirrhosis.
METHODS: Forty-six Sprague-Dawley rats with CCl4 -induced cirrhosis were randomized into two groups: VSL#3 group (n = 22) that received VSL#3 in drinking water, and water group (n = 24) that received water only. Treatment began at week 6 of cirrhosis induction and continued until laparotomy, performed 1 week after development of ascites or at week 20. A control group included 11 healthy rats. At this study end, we evaluated bacterial translocation, intestinal flora, intestinal barrier (ileal claudin-2 and 4, β-defensin-1, occludin and malondialdehyde as index of oxidative damage) and serum cytokines.
RESULTS: Mortality during this study was similar in the VSL#3 group (10/22, 45%) and the water group (10/24, 42%) (P = 1). The incidence of bacterial translocation was 1/12 (8%) in the VSL#3 group, 7/14 (50%) in the water group (P = 0.03 vs. VSL#3 group) and 0/11 in the control group (P = 0.008 vs. water group). The concentration of ileal and caecal enterobacteria and enterococci was similar in the two groups of cirrhotic rats. The ileal occludin concentration was higher and ileal malondialdehyde and serum levels of TNF-α were lower in the VSL#3 group than in the water group (P < 0.05).
CONCLUSIONS: VSL#3 decreases bacterial translocation, the pro-inflammatory state and ileal oxidative damage and increases ileal occludin expression in rats with experimental cirrhosis.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  experimental model; inflammatory response; intestinal barrier; liver damage; microbiota

Mesh:

Substances:

Year:  2014        PMID: 24750552     DOI: 10.1111/liv.12566

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  15 in total

Review 1.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Gut microbiome and liver disease.

Authors:  Naga S Betrapally; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Transl Res       Date:  2016-07-15       Impact factor: 7.012

3.  Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis.

Authors:  Alba Moratalla; Isabel Gómez-Hurtado; Ángela Moya-Pérez; Pedro Zapater; Gloria Peiró; José M González-Navajas; Eva Maria Gómez Del Pulgar; José Such; Yolanda Sanz; Rubén Francés
Journal:  Eur J Nutr       Date:  2015-02-06       Impact factor: 5.614

Review 4.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

5.  Assessing the Safety and Efficacy of Lactobacillus plantarum MTCC 5690 and Lactobacillus fermentum MTCC 5689 in Colitis Mouse Model.

Authors:  Diwas Pradhan; Rajbir Singh; Ashish Tyagi; Rashmi H M; Virender K Batish; Sunita Grover
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

Review 6.  Novel prevention strategies for bacterial infections in cirrhosis.

Authors:  Kathleen Yan; Guadalupe Garcia-Tsao
Journal:  Expert Opin Pharmacother       Date:  2016-02-23       Impact factor: 3.889

7.  Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition.

Authors:  Ming Li; Lin Zhu; Ao Xie; Jieli Yuan
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 8.  Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis.

Authors:  Pedro Zapater; José Manuel González-Navajas; José Such; Rubén Francés
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 9.  Probiotics in critically ill children.

Authors:  Sunit C Singhi; Suresh Kumar
Journal:  F1000Res       Date:  2016-03-29

10.  Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication between the Peripheral Immune System and the Brain.

Authors:  Charlotte D'Mello; Natalie Ronaghan; Raza Zaheer; Michael Dicay; Tai Le; Wallace K MacNaughton; Michael G Surrette; Mark G Swain
Journal:  J Neurosci       Date:  2015-07-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.